publication date: Jun. 9, 2017
Conversation with The Cancer Letter Maria Koehler: Real-world data is “truly a revolution”
Vice President of oncology strategy, innovation and collaborations, Pfizer Oncology
Real-world evidence is more than just another way of tracking post-market patterns in drug utilization, said Maria Koehler, vice president of oncology strategy, innovation and collaborations at Pfizer Oncology.
New technology for tracking real-world data may soon change the way pharmaceutical companies approach drug development. By analyzing real-time data, industry can use robust evidence from oncology practices to update drug labels, track market trends, and adjust production.
“For example, let’s look at anti-VEGF drugs like Avastin,” Koehler said. “If Avastin is used in non-small cell lung cancer, but a better drug is coming, then, of course, the Avastin segment would decrease dramatically, because the new drug is presumably better.
“This is the key here—presumably better, because there is no direct comparison between angiogenesis inhibitors and PD-1. But the market is telling us how it interprets the trial data or how physicians interpret the data. This is where the value is—truly.”
Koehler agreed to review drug utilization data compiled by Flatiron Health and made available to The Cancer Letter. The dataset tracks the uptake of PD-1 checkpoint inhibitor drugs in nearly 35,000 non-small cell lung … Continue reading Maria Koehler: Real-world data is “truly a revolution”
To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us
and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.